InVivo in the News

(Reuters) Invivo therapeutics announces update on the inspire study and fda approval of expansion of the study to 20 evaluable patients. Announced that 9th and 10th patients have been implanted with neuro-spinal scaffold in inspire study

(Seeking Alpha) Thinly traded micro cap InVivo Therapeutics Holdings (NASDAQ:NVIV) is up 6% premarket on light volume in response to its announcement that the 9th and 10th subjects have been implanted in its 20-subject Phase 3 clinical trial, INSPIRE, assessing the Neuro-Spinal Scaffold™ in patients with acute spinal cord injury.

(Fly On The Wall) InVivo Therapeutics announced that the 9th and 10th patients have been implanted with the Neuro-Spinal Scaffold™ in the INSPIRE study. The 9th patient was implanted at Vidant Medical Center, a Level 1 trauma center located in Greenville, North Carolina.

(Becker’s Spine Review) Cambridge, Mass.-based InVivo Therapeutics named Christina Morrison to its board of directors.

(TheStreet) InVivo Therapeutics (NVIV) , a research and clinical-stage biomaterials and biotechnology company, focus on developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. This stock traded up 4.3% to $6.68 in Friday’s trading session…

(Becker’s Spine Review) WBZ NewsRadio 1030 featured InVivo Therapeutics on its radio broadcast.

(Becker’s Spine Review) The U.S. Patent and Trademark Office issued InVivo Therapeutics a Notice of Allowance for the U.S. Patent Application, “Methods and Compositions for the Treatment of Open and Closed Wound Spinal Cord Injuries.”

(MassDevice) InVivo Therapeutics (NSDQ:NVIV) said today it added Philadelphia’s Hospital of the University of Pennsylvania as a site in the Inspire study of its neuro-spinal scaffold, bringing the total number of sites up to 20.

(Becker’s Spine Review) InVivo Therapeutics added Philadelphia-based University of Pennsylvania as a clinical site for the INSPIRE study.

(Life Science Reader) Let me tell you what I’ve been doing the last few months and why you haven’t seen a blog from me during all that time. Two activities have accounted for most of my workload — writing and travel. But of the two, writing has taken the lion’s share. I don’t mean the kind of writing I’m doing now, scribing down thoughts right out of my memory and imagination. I mean the sort of writing where most of the work takes place well before I press the first key for the first letter in the first draft. One series of articles now underway has so far required 16 interviews, some by phone, others on the road.